- 基本信息
导师姓名:
|
刘晗
|
学科代码:
|
100201
|
|
性别:
|
男
|
学科名称:
|
内科学
|
培养单位:
|
附属瑞金医院
|
三级学科
|
血液病
|
导师类型:
|
博士生导师
|
专业领域名称:
|
|
联系方式:
|
021-64370045-610620
|
专业领域代码:
|
|
邮编:
|
200025
|
邮箱地址:
|
liuhan68@yahoo.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
|
美国血液学会 Active Member
|
中国病理生理学会实验血液学专业委员会委员
|
中国细胞生物学学会细胞治疗研究与应用分会理事
|
- 科研项目
20161304 | CAR-T免疫治疗中抗原逃逸的机制及其干预 | 上海交通大学医学院高峰高原计划 —“临床专职科研队伍”(第二轮) |
2020-01~2022-12
|
100万元
| 课题负责人 |
81973996 | MLL白血病细胞对蛋白酶体抑制剂耐受的表观遗传机制研究 | 国家自然科学基金面上项目 |
2020-01~2023-12
|
55万元
| 课题负责人 |
19XD1402500 | 人 iPS 来源的造血干祖细胞的重编程技术开发与优化 | 上海市优秀学术带头人计划 |
2019-05~2022-04
|
40万元
| 课题负责人 |
2018YFA0107800 | 正常及病变血液系统细胞分化图谱研究 | 国家重点研发计划“干细胞及转化研究”重点专项 |
2018-07~2022-12
|
2920万元
| 课题负责人 |
20161304 | MLL白血病精准免疫治疗研究 | 上海交通大学医学院高峰高原计划 —“临床专职科研队伍”
|
2016-07~2019-12
|
50万元
| 课题负责人 |
81570119 | 未折叠蛋白反应在MLL白血病细胞对蛋白酶体抑制剂敏感性中的作用 | 国家自然科学基金面上项目 |
2016-01~2019-12
|
60万元
| 课题负责人 |
XYXT2015102 | MLL白血病的新型CAR-T治疗研究 | 血液学协同创新中心协同创新重大任务 |
2016-01~2016-12
|
46万元
| 课题负责人 |
14SG15 | 应用蛋白酶体抑制剂治疗MLL白血病的分子机制及耐药机制研究 | 上海市曙光计划 |
2015-03~2017-12
|
15万元
| 课题负责人 |
81370651 | 利用MLL融合蛋白的内在肿瘤抑制活性进行MLL白血病靶向治疗的转化研究 | 国家自然科学基金面上项目 |
2014-01~2017-12
|
70万元
| 课题负责人 |
- 学术论文
Shi B, Li D, Yao W, Wang W, Jiang J, Wang R, Yan F,, Zhang H*, Ye J*
|
Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma
|
Biomater Sci
|
2022
|
10(10):2577-2589. (IF2022=6.6)
|
Sun Y, Wang R, Xie S, Wang Y,
|
A Novel Identified Necroptosis-Related Risk Signature for Prognosis Prediction and Immune Infiltration Indication in Acute Myeloid Leukemia Patients
|
Genes
|
2022
|
13(10):1837. (IF2022=3.5)
|
Li D, Wang W, Xie S, Ge M, Wang R, Xu Q, Sun Y, Zhu J,
|
A T-cell independent universal cellular therapy strategy through antigen depletion
|
Theranostics
|
2022
|
12(3):1148-1160. (IF2022=12.4)
|
Wang RH*, Xie SF, Zhu SH, Sun Y, Shi BW, Li D, Kang T, Wang YL, Xu ZS*,
|
Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia
|
Cell Death Discov
|
2022
|
8(1): 180. (IF2022=7)
|
Li D, Xu QY, Hu YT, Wang WB, Xie SF, Zhao CJ,
|
Tumor-intrinsic CD21 expression impacts the response of B-cell malignancy cells to CD19-CAR-T cells
|
J Leukoc Biol
|
2022
|
112(4):913-918. (IF2022=5.5)
|
Ge ML#, Qiao Z, Kong Y, Liang HY, Sun Y, Lu H, Xu ZS#,
|
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance
|
Br J Cancer
|
2021
|
124(4):770-776. (IF2021=9.075, , Highlighted in Br J Cancer)
|
Ge M#, Xu Q, Kang T, Li D, Wang R, Chen Z, Xie S, Wang W,
|
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
|
Cancer Sci
|
2021
|
112(6):2287-2298. (IF2021=6.518)
|
Zhu SH, Chen ZH, Jiang D, Wang RH, Cheng XY, Li D, Xu QY, Zhao F, Kim W, Guo GJ, Zhao CJ, Lou ZK#,
|
Mixed-lineage leukemia protein modulates the loading of let-7a onto AGO1 by recruiting RAN
|
Haematologica
|
2021
|
106(7):1995-1999. (IF2021=11.047)
|
Cheng XY, Ge ML, Zhu SH, Li D, Wang RH, Xu QY, Chen ZH, Xie SF,
|
mTORC1‐mediated amino acid signaling is critical for cell fate determination under transplant‐induced stress
|
FEBS Lett
|
2021
|
595(4):462-475. (IF2021=3.864)
|
Ge ML, Li D, Qiao Z, Sun Y, Kang T, Zhu SH, Wang SF, Xiao H, Zhao CJ, Shen SH#, Xu ZS#,
|
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors
|
Oncogene
|
2020
|
39(36):5888-5901. (IF2020=9.867)
|
Zhu SH, Cheng XY, Wang RH, Tan YT, Ge ML, Li D, Xu QY, Sun Y, Zhao CJ, Chen SJ,
|
Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia
|
Leukemia
|
2020
|
34(9):2484-2488. (IF2020=11.528)
|
Ge ML#, Qiao Z, Kong Y, Lu H,
|
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia
|
Cancer Sci
|
2020
|
111(4):1279-1290. (IF2020=6.716)
|
Tan YT#, Ye L, Xie F, Wang J, Müschen M, Chen SJ#, Kan YW#,
|
The CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1T315I mutation mouse model
|
Haematologica
|
2020
|
105(5): e232-e236. (IF2020=9.941)
|
Kang T, Ge ML, Wang RH, Tan Z, Zhang XL, Zhu CY,, Chen SY#
|
Arsenic sulfide induces RAG1-dependent DNA damage for cell killing by inhibiting NFATc3 in gastric cancer cells
|
J Exp Clin Cancer Res
|
2019
|
38:487. (IF2019=7.068)
|
Wang SF, Ge ML, Cui J, Qiao Z, Chen X, Wu S, Zhan R, Zhou H,, Xu ZS#
|
Diminished interaction between mutant NOTCH1 and the NuRD co-repressor complex upregulates CCL17 in chronic lymphocytic leukemia
|
Leukemia
|
2019
|
33(12):2951-6. (IF2019=8.665)
|
Zhu SH, Chen ZH, Wang RH, Tan YT, Ge ML, Sun Y, Li D, Hu YT, Zhao CJ, Chen Z, Chen SJ,
|
MLL is required for miRNA-mediated translational repression
|
Cell Discov
|
2019
|
5:43. (IF2019=6.255)
|
Tan YT, Ye L, Xie F, Beyer AI, Muench MO, Wang J, Chen Z,, Chen SJ#, Kan YW#
|
Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor
|
Proc Natl Acad Sci U S A
|
2018
|
115(9):2180-5. (IF2018=9.580, Highlighted in PNAS, F1000)
|
Li D, Hu Y, Jin Z, Zhai Y, Tan Y, Sun Y, Zhu S, Zhao C, Chen B, Zhu J, Chen Z, Chen S, Li J,
|
TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells
|
Leukemia
|
2018
|
32(9):2012-6. (IF2018=9.944)
|
Tan YT, Sun Y, Zhu SH, Ye L, Zhao CJ, Zhao WL, Chen Z, Chen SJ#,
|
Deregulation of HOX genes by DNMT3A and MLL mutations converges on BMI1
|
Leukemia
|
2016
|
30:1609-12. (IF2016=11.702)
|
, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ
|
Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias Through MLL-AF4
|
Cancer Cell
|
2014
|
25(4):530-42. (IF2014=23.523, Highlighted in Cancer Cell, Cancer Discovery)
|
, Takeda S, Kumar R, Westergard T, Brown E, Pandita T, Cheng EH, Hsieh JJ
|
Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint
|
Nature
|
2010
|
467:343-6. (IF2010=36.101, Highlighted in Mol Cell, F1000)
|
, Westergard TD, Hsieh JJ
|
MLL5 governs hematopoiesis: a step closer
|
Blood
|
2009
|
113:1395-6. (IF2009=10.555)
|
, Cheng EH, Hsieh JJ
|
MLL fusions: Pathways to leukemia
|
Cancer Biol Ther
|
2009
|
8:1204-11. (IF2009=2.711)
|
, Takeda S, Cheng EH, Hsieh JJ
|
Biphasic MLL takes helm at cell cycle control: Implications in human mixed lineage leukemia
|
Cell Cycle
|
2008
|
7:428-35. (IF2008=4.12)
|
, Cheng EH, Hsieh JJ
|
Bimodal degradation of MLL by SCFSkp2 andAPCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions
|
Genes Dev
|
2007
|
21:2385-98. (IF2007=14.795, Highlighted in F1000)
|
Ma LH*,, Xiong H*, Chen B, Zhang XW, Wang YY, Le HY, Huang QH, Zhang QH, Li BL, Chen Z, Chen SJ
|
Aberrant transcriptional regulation of the MLL fusion partner EEN gene by AML1-ETO andits implication in leukemogenesis
|
Blood
|
2007
|
109:769-77. (IF2007=10.896)
|
|